Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.73 |
| ▸ | USP2 | O75604 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.73 |
| ▸ | FPR2 | P25090 | 10/20 | 0.71 |
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 3/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561399 | 0.96 | LMNA (0.75) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL26002991 | 0.86 | LMNA (0.62) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL7746782 | 0.86 | FPR2 (0.69) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL8218991 | 0.86 | LMNA (0.98) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL24439717 | 0.86 | FPR2 (0.78) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL14724203 | 0.86 | TP53 (0.72) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL14809956 | 0.86 | TP53 (0.72) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| Ammonia Solution, Strong SCHEMBL6944606 | 0.85 | TP53 (0.71) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| Dimethylamine SCHEMBL7750171 | 0.84 | TP53 (0.69) | LMNAMAPTNPSR1SMN1; SMN2MEN1 | |
| SCHEMBL6867284 | 0.83 | PIM1 (0.69) | LMNAMAPTNPSR1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210061837-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2021-03-04 | — | — | US | disclosed |
| US-20210061837-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2021-03-04 | — | — | US | disclosed |
| WO-2019195789-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-31 | — | — | US | disclosed |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2061788-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | Immune Control, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008027521-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | IMMUNE CONTROL, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061837-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | LMNA 546/4885MAPT 651/4885NPSR1 4043/4885 |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | LMNA 546/4885MAPT 651/4885NPSR1 4043/4885 |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | CALM1, CAMK4, CAMK1 | LMNA 2841/4885MAPT 655/4885NPSR1 2991/4885 |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | LMNA 1395/4885MAPT 2358/4885NPSR1 107/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | LMNA 546/4885MAPT 651/4885NPSR1 4043/4885 |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | NFATC1, BAX, BCL2 | LMNA 301/4885MAPT 3914/4885NPSR1 2714/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | LMNA 1482/4885MAPT 2819/4885NPSR1 73/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | LMNA 546/4885MAPT 651/4885NPSR1 4043/4885 |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | LMNA 546/4885MAPT 651/4885NPSR1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.